ESMO 2021 Report — Breast Cancer

Highlights of the latest treatments

At this year's European Society of Medical Oncology (ESMO) Congress — held virtually September 16 to 21 in Paris, France — investigators reported the latest findings in cancer research. Here, NEJM Journal Watch Oncology and Hematology Editor-in-Chief William J. Gradishar reviews key presentations of new breast cancer therapies. All abstracts can be accessed via ESMO 2021 Oncology Meeting Resources.

Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in HER2-Positive MBC

One of the most awaited presentations was DESTINY-Breast03, an industry-sponsored randomized phase 3 trial of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) as second-line therapy for HER2-positive metastatic breast cancer (MBC; abstract LBA1). The current…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)